NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free VINC Stock Alerts $0.73 -0.17 (-18.89%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.8550-Day Range$0.73▼$8.0652-Week Range$0.61▼$9.37Volume1.73 million shsAverage Volume1.67 million shsMarket Capitalization$15.63 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vincerx Pharma alerts: Email Address Vincerx Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside584.9% Upside$5.00 Price TargetShort InterestBearish8.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector668th out of 913 stocksPharmaceutical Preparations Industry306th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVincerx Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.91% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently increased by 50.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 1.6 News and Social Media Coverage News SentimentVincerx Pharma has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vincerx Pharma this week, compared to 1 article on an average week.Search Interest92 people have searched for VINC on MarketBeat in the last 30 days. This is an increase of 441% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to decrease in the coming year, from ($0.97) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Vincerx Pharma Stock (NASDAQ:VINC)Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More VINC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VINC Stock News HeadlinesApril 28, 2024 | americanbankingnews.comShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 50.0%April 26, 2024 | msn.comWhy Vincerx Pharma (VINC) Stock Is FallingApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 26, 2024 | globenewswire.comVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsApril 25, 2024 | globenewswire.comVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsApril 23, 2024 | nasdaq.comVincerx Pharma, Inc. Common Stock (VINC)April 12, 2024 | finance.yahoo.comAgendia’s BluePrint Included in German Oncology Group GuidelinesApril 10, 2024 | finance.yahoo.comThe Rise of Zyn: The Oral Nicotine Product Going ViralApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 10, 2024 | markets.businessinsider.comVincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersApril 9, 2024 | msn.comACOR, HUBC and DATS among pre-market losersApril 9, 2024 | msn.comVincerx in selloff after early-stage data for cancer therapyApril 9, 2024 | investorplace.comWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?April 8, 2024 | globenewswire.comVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024April 2, 2024 | investorplace.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023April 1, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateApril 1, 2024 | finance.yahoo.comVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 29, 2024 | finance.yahoo.comVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close LookMarch 29, 2024 | marketwatch.comVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024March 29, 2024 | globenewswire.comVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 19, 2024 | edition.cnn.comVincerx Pharma IncMarch 12, 2024 | benzinga.comWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug PipelineMarch 5, 2024 | globenewswire.comVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024March 5, 2024 | finance.yahoo.comVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekFebruary 22, 2024 | morningstar.comVincerx Pharma Inc Ordinary Shares VINCFebruary 22, 2024 | benzinga.comVincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and DatesSee More Headlines Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+584.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-187.73% Return on Assets-126.26% Debt Debt-to-Equity RatioN/A Current Ratio2.63 Quick Ratio2.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book1.40Miscellaneous Outstanding Shares21,410,000Free Float17,002,000Market Cap$15.63 million OptionableNot Optionable Beta1.10 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 59)Co-Founder, Chairman & CEO Comp: $657.54kDr. Raquel E. Izumi Ph.D. (Age 54)Co-Founder, President, COO, Secretary & Director Comp: $591.54kMr. Alexander A. Seelenberger M.B.A. (Age 45)Chief Financial Officer Comp: $491.69kMr. Tom C. Thomas J.D. (Age 64)Founder, General Counsel & Chief Legal Officer Comp: $444.14kDr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardDr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Gabriela JairalaSr Executive Director of Investor Relations & Corporate CommunicationsMs. Karen QuarfordVice President of Quality Operations & ComplianceMs. Melissa Merrick SPHRSenior Director of People & Culture and Head of Human ResourceDr. Beatrix Stelte-Ludwig Ph.D.Executive Chief Development OfficerMore ExecutivesKey CompetitorsRenovoRxNASDAQ:RNXTAddex TherapeuticsNASDAQ:ADXNOnconova TherapeuticsNASDAQ:ONTXAptorum GroupNASDAQ:APMBioVieNASDAQ:BIVIView All CompetitorsInsidersAlexander A SeelenbergerBought 10,500 shares on 8/11/2023Total: $9,975.00 ($0.95/share)Ahmed Md HamdyBought 16,900 shares on 8/9/2023Total: $16,055.00 ($0.95/share)View All Insider Transactions VINC Stock Analysis - Frequently Asked Questions Should I buy or sell Vincerx Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks. What is Vincerx Pharma's stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for Vincerx Pharma's shares. Their VINC share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts. How have VINC shares performed in 2024? Vincerx Pharma's stock was trading at $1.18 on January 1st, 2024. Since then, VINC shares have decreased by 38.1% and is now trading at $0.73. View the best growth stocks for 2024 here. Are investors shorting Vincerx Pharma? Vincerx Pharma saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,200,000 shares, an increase of 50.0% from the March 31st total of 799,900 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is presently 1.1 days. Approximately 8.9% of the company's stock are sold short. View Vincerx Pharma's Short Interest. When is Vincerx Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VINC earnings forecast. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) announced its quarterly earnings data on Friday, March, 29th. The company reported ($0.23) EPS for the quarter. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VINC) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
